Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.
Saved in:
| Title: | Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. |
|---|---|
| Authors: | Qin S; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Fan L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Liang J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Gale R; Department of Medicine, Imperial College London, Centre for Haematology, Division of Experimental Medicine, London, UK., Miao Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wang R; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Yang H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Xia Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Zhu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wang L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Xu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Li J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China. |
| Source: | Hematological oncology [Hematol Oncol] 2018 Oct; Vol. 36 (4), pp. 656-662. Date of Electronic Publication: 2018 Jun 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.2520 |
